Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 15/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13570886 | 0.81 | GLS (0.52) | GLSSORT1RIPK1 | |
| SCHEMBL11666512 | 0.81 | RHOC (0.53) | GLSSORT1HDAC1 | |
| SCHEMBL507223 | 0.79 | MLYCD (0.51) | GLSSORT1PPARGHDAC1 | |
| SCHEMBL17092135 | 0.78 | LMNA (0.48) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL30565175 | 0.77 | GLS (0.48) | GLSSORT1RIPK1 | |
| SCHEMBL17092307 | 0.75 | HSD17B13 (0.50) | GLS | |
| SCHEMBL18352884 | 0.75 | GLS (0.53) | GLSSORT1 | |
| SCHEMBL29351249 | 0.75 | GLS (0.53) | GLSSORT1 | |
| SCHEMBL29349720 | 0.74 | GLS (0.51) | GLSSORT1 | |
| SCHEMBL15646326 | 0.74 | NAMPT (0.58) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20150266856-A1 | RORGamma Modulators | EXELIXIS, INC. | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266856-A1 | RORGamma Modulators | RORB, RORA, RORC | GLS 1778/4885SORT1 4567/4885RIPK1 2032/4885 |
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | GLS 1318/4885SORT1 4215/4885RIPK1 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.